Clinical Trial Update: Changes in NT-proBNP, Safety, and Tolerability in HFpEF Patients With a WHF Event (HFpEF Decompensation) Who Have Been Stabilized and Initiated at the Time of or Within 30 Days Post-decompensation (PARAGLIDE-HF) [Phase 3]

View source ↗

Summary

Phase 3 trial PARAGLIDE-HF in heart failure with preserved ejection fraction patients after decompensation reports NT-proBNP changes, safety, and tolerability; …

Upgrade for the full analysis, importance score, and drug timeline.

Diseases / indications

• Heart Failure with Preserved Ejection Fraction

Drugs mentioned

• PARAGLIDE

Snippet

Sponsor: Novartis Pharmaceuticals | Conditions: Heart Failure With Preserved Ejection Fraction (HFpEF) | Phase 3 | Status: COMPLETED | Results posted: 2024-07-29